Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · IEX Real-Time Price · USD
43.43
+0.24 (0.56%)
At close: May 7, 2024, 4:00 PM
42.59
-0.84 (-1.93%)
After-hours: May 7, 2024, 5:27 PM EDT
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for XENE stock have an average target of 58.3, with a low estimate of 49 and a high estimate of 65. The average target predicts an increase of 34.24% from the current stock price of 43.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for XENE stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 5 | 5 | 5 |
| Buy | 7 | 6 | 6 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $62 | Strong Buy | Reiterates | $62 | +42.76% | Apr 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +49.67% | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $56 → $55 | Buy | Maintains | $56 → $55 | +26.64% | Mar 1, 2024 |
| Wedbush | Wedbush | Buy Maintains $46 → $51 | Buy | Maintains | $46 → $51 | +17.43% | Mar 1, 2024 |
| Needham | Needham | Strong Buy Maintains $50 → $62 | Strong Buy | Maintains | $50 → $62 | +42.76% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
2.61M
Revenue Next Year
5.75M
from 2.61M
Increased by 119.93%
EPS This Year
-2.97
from -2.73
EPS Next Year
-3.36
from -2.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.3M | 73.7M | 113.5M | 961.7M | 1.3B |
| Avg | 2.6M | 5.7M | 80.4M | 316.2M | 561.4M |
| Low | n/a | n/a | 40.6M | 5.2M | 53.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 2,720.6% | 1,874.8% | 1,095.6% | 319.0% |
| Avg | - | 119.9% | 1,299.2% | 293.1% | 77.5% |
| Low | - | - | 605.7% | -93.6% | -83.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.47 | -1.17 | -1.85 | 1.95 | 4.86 |
| Avg | -2.97 | -3.36 | -3.25 | -1.45 | 0.70 |
| Low | -3.47 | -4.38 | -4.11 | -3.19 | -1.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.